Clinical Report: Momelotinib in Myelofibrosis—14 Years of Clinical Trial Insights
Overview
Momelotinib, a JAK inhibitor with unique erythropoietic effects, was recently FDA-approved for anemic patients with high/intermediate-risk myelofibrosis. Over 14 years and 100 clinical trial participants, momelotinib demonstrated clinical improvements in anemia, splenomegaly, and symptom control with a manageable safety profile.
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, constitutional symptoms, and progressive anemia, leading to poor survival outcomes. Treatment aims to prolong survival and improve quality of life, with allogeneic hematopoietic stem cell transplantation being the only curative option. Janus kinase inhibitors (JAKi) target the JAK-STAT pathway driving MF symptoms but have not induced molecular remissions. Momelotinib uniquely inhibits ACVR1 (ALK2), contributing to its erythropoietic effects and addressing anemia in MF patients.
Data Highlights
Parameter
Value/Outcome
Number of patients in phase 1/2 trial
166 (100 at Mayo Clinic)
Dose range
100-400 mg once daily; confirmation at 150 or 300 mg
Clinical improvement rate
57%
Anemia response
45-54%
Resolution of transfusion need
53%
Spleen response
40-42%
Grade 3/4 thrombocytopenia
32-34%
Peripheral neuropathy incidence
44%
Median onset of neuropathy
32 weeks
Key Findings
Momelotinib inhibits JAK1, JAK2, JAK3, TYK2, and ACVR1, contributing to symptom control and erythropoiesis.
In phase 1/2 trials, momelotinib showed 57% clinical improvement and 45-54% anemia response in MF patients.
Resolution of transfusion dependence was achieved in over half of treated patients (53%).
Spleen response was observed in approximately 40-42% of patients, improving splenomegaly-related symptoms.
Peripheral neuropathy occurred in 44% of patients, typically emerging around 32 weeks, with some improvement after dose adjustment.
Higher momelotinib doses (300 mg) were associated with increased peripheral neuropathy and diarrhea compared to 150 mg.
Clinical Implications
Momelotinib offers a valuable treatment option for anemic patients with high/intermediate-risk myelofibrosis, addressing both anemia and splenomegaly. Clinicians should monitor for peripheral neuropathy, especially with higher doses, and consider dose adjustments to manage adverse effects. Its recent FDA approval expands therapeutic choices beyond existing JAK inhibitors, particularly for patients with transfusion-dependent anemia.
Conclusion
Fourteen years of clinical experience demonstrate that momelotinib is effective in improving anemia, reducing transfusion needs, and controlling splenomegaly in MF patients, with a manageable safety profile. Its unique mechanism targeting ACVR1 distinguishes it from other JAK inhibitors and supports its role in MF management.
References
Tefferi et al. 2023 -- Momelotinib in Myelofibrosis: 14 Years of Experience and FDA Approval
